Severe Asthma Exacerbation With a Deceptively Normal PaCO2
A 24-year-old woman with asthma presents after 2 days of a viral upper respiratory infection. She is sitting upright, speaking in short phrases, and using accessory muscles. Respiratory rate 32/min, heart rate 128/min, SpO2 91% on room air, peak expiratory flow 35% of her personal best. She has received three albuterol nebulizer treatments (2.5 mg each) and ipratropium 0.5 mg in the emergency department, plus oral prednisone 60 mg. Wheezing is audible without a stethoscope, but airflow is decreasing. Arterial blood gas on room air: pH 7.48, PaCO2 30 mm Hg, PaO2 65 mm Hg, HCO3 23 mEq/L. Chest radiograph is hyperinflated without infiltrate. The emergency physician asks about continuous nebulized albuterol, IV magnesium, and whether noninvasive ventilation or intubation is needed.
1. How severe is this exacerbation, and how do you interpret the ABG?
Read the worked answer
This is a severe asthma exacerbation: peak expiratory flow is only 35% of personal best, SpO2 is 91% on room air, respiratory rate is 32/min, heart rate is 128/min, and she can speak only short phrases with accessory muscle use. The ABG shows respiratory alkalosis with mild hypoxemia: pH 7.48, PaCO2 30 mm Hg, PaO2 65 mm Hg. Early in a severe attack, hyperventilation lowers PaCO2, so a low CO2 is expected. The dangerous misinterpretation is to treat a subsequent PaCO2 of 40 mm Hg as normal or improved. In a tachypneic, exhausted asthmatic, a rising or normalizing PaCO2 signals fatigue and impending respiratory failure. The decreasing airflow and audible wheeze are also warning signs, not reassuring findings.
2. Outline immediate pharmacologic therapy, including magnesium and delivery method, and what adverse effects you monitor.
Read the worked answer
Give oxygen to maintain SpO2 93–95%. Start continuous nebulized albuterol at 10–20 mg/hour rather than repeated small intermittent doses. Add ipratropium 0.5 mg every 20 minutes for up to three doses, then every 4–6 hours. Continue systemic corticosteroids; if she cannot take oral medication reliably, use methylprednisolone 60–80 mg IV every 6–12 hours. Give magnesium sulfate 2 g IV over about 20 minutes for severe exacerbation. Monitor heart rate, blood pressure, tremor, potassium, lactate, and ECG if there is cardiac risk, because beta-agonists cause tachycardia, hypokalemia, and hyperlactatemia. Nebulized therapy is appropriate in severe distress; an MDI with spacer is reasonable only when the patient can cooperate and is not in severe distress. Avoid sedatives and do not rely on theophylline.
3. Would you use noninvasive ventilation or proceed to intubation? Give criteria.
Read the worked answer
Noninvasive ventilation is not routine in severe asthma and can delay intubation if the patient is tiring. It may be considered only in an alert patient who is not exhausted, with close one-to-one monitoring and a clear plan to intubate if there is no rapid improvement. Intubate for altered mental status, exhaustion, a silent chest, rising PaCO2, refractory hypoxemia, apnea, or inability to protect the airway. In this patient, a PaCO2 that rises toward 40 mm Hg with worsening airflow would be an indication for intubation, not observation. If intubating, use ketamine for induction, a low tidal volume around 6–8 mL/kg predicted body weight, a high inspiratory flow to shorten expiratory time, and careful monitoring for auto-PEEP and hypotension.